Your session is about to expire
← Back to Search
Metformin for COVID-19
This trial is testing if repurposed drugs can reduce symptoms of mild-moderate COVID-19, with participants taking either the drug or a placebo. All visits will be remote, with clinicaltrials.gov listing each drug arm.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2015 Phase 4 trial • 156 Patients • NCT02002221
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available spots for participants in this experiment?
"Clinicaltrials.gov reveals that this medical trial is quickly seeking participants, having first been announced on September 5th 2023 and most recently updated 19 days later."
How many places can patients access this trial?
"This trial is currently present at 5 distinct medical institutions, including Northwestern University in Chicago, the University of Minnesota in Minneapolis, and Duke Clinical Research Institute in Durham. There are also an additional five sites hosting this study."
What is the recruitment size of this research endeavor?
"15000 volunteers that satisfy the specified inclusion criteria are needed to complete this study. The trials can be conducted at two of the many approved facilities, like Northwestern Univesity in Chicago, Illinois and University of Minnesota, Illinois and University of Minnesota in Minneapolis, Minnesota."
Has the Food and Drug Administration given its stamp of approval to Arm G - Metformin?
"We at Power rate the safety of Arm G - Metformin to be a 3 on account of its Phase 3 trial status; providing evidence that it is efficacious and has been affirmed as safe."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends